Comparative Pharmacology
Head-to-head clinical analysis: MVC PLUS versus RUVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MVC PLUS versus RUVITE.
MVC PLUS vs RUVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MVC PLUS is a fixed-dose combination of maraviroc, a CCR5 co-receptor antagonist, and lamivudine, a nucleoside reverse transcriptase inhibitor. Maraviroc binds to CCR5 on CD4+ T cells blocking HIV-1 entry; lamivudine inhibits HIV reverse transcriptase via competitive inhibition and chain termination.
RUVITE (ruxolitinib) is a Janus kinase (JAK) inhibitor, specifically inhibiting JAK1 and JAK2, which mediates signaling of cytokines and growth factors involved in hematopoiesis and immune function.
10 mg orally once daily.
100 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours (mean 14 hours). Clinically, this supports twice-daily dosing with steady-state achieved in ~3 days.
The terminal elimination half-life is approximately 2-4 hours in patients with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), the half-life may be prolonged to 8-12 hours, necessitating dose adjustment.
Renal: ~70% unchanged; Fecal: ~25%; Biliary: <5%
Renal excretion of unchanged drug accounts for approximately 30-50% of the administered dose; biliary/fecal elimination accounts for the remainder, with 20-30% recovered in feces as metabolites and parent drug. Total clearance is about 100-150 mL/min.
Category C
Category C
Multivitamin/Mineral Supplement
Multivitamin